QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NASDAQ:AZN

AstraZeneca - AZN Price Target & Analyst Ratings

$66.74
+1.13 (+1.72%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$65.79
$66.77
50-Day Range
$64.10
$70.34
52-Week Range
$52.65
$72.12
Volume
3.99 million shs
Average Volume
5.30 million shs
Market Capitalization
$206.87 billion
P/E Ratio
62.37
Dividend Yield
2.89%
Price Target
$126.00

AstraZeneca Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 8 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
3/20/22 to 3/20/23
1 Month Ago
2/18/22 to 2/18/23
3 Months Ago
12/20/21 to 12/20/22
1 Year Ago
3/20/21 to 3/20/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
9 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/A$70.00$70.00$62.00
Predicted UpsideN/A15.63% Upside15.63% Upside6.94% Upside
Get AstraZeneca Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AZN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.64
2.47
Consensus RatingHoldBuyHold
Predicted Upside1,930.50% Upside23.26% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/21/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£101 ➝ £119
1/18/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetGBX 118 ➝ GBX 126
1/5/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£125 ➝ £135
12/15/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£120 ➝ £130
10/11/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target£120 ➝ £118
9/15/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
9/7/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
8/29/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
8/22/2022AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce
7/12/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£105 ➝ £130
5/24/2022Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/18/2022Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
4/14/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£115 ➝ £120
2/28/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
2/24/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$65.00 ➝ $70.00+15.63%
2/11/2022DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
12/7/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$54.00-2.54%
11/22/2021Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy
3/23/2021Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
12/13/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$179.00 ➝ $175.00+222.46%
11/11/2020HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold
9/23/2020Oddo Bhf
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Buy
6/10/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Steve Scala
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$55.00 ➝ $60.00+11.32%
4/23/2020FIG Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageReduce
(Data available from 3/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AZN Price Target - Frequently Asked Questions

What is AstraZeneca's consensus rating?

According to the issued ratings of 8 analysts in the last year, the consensus rating for AstraZeneca stock is Hold based on the current 1 sell rating, 4 hold ratings and 3 buy ratings for AZNthe . Learn more on AZN's analyst rating history.

Do Wall Street analysts like AstraZeneca more than its competitors?

Analysts like AstraZeneca less than other Medical companies. The consensus rating for AstraZeneca is Hold while the average consensus rating for medical companies is Buy. Learn more on how AZN compares to other companies.

What analysts cover AstraZeneca?

AstraZeneca has been rated by Berenberg Bank, BMO Capital Markets, JPMorgan Chase & Co., and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AZN) was last updated on 3/20/2023 by MarketBeat.com Staff